How are TMO strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TMO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,490.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a TMO strangle?

The breakeven for the TMO strangle priced on this page is roughly $455.10 and $554.90 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TMO market-implied 1-standard-deviation expected move is approximately 10.72%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current TMO implied volatility affect this strangle?

TMO ATM IV is at 37.40% with IV rank near 82.38%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.

TMO Strangle Strategy

TMO (Thermo Fisher Scientific Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments.

TMO (Thermo Fisher Scientific Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $190.65B, a trailing P/E of 27.82, a beta of 0.87 versus the broader market, a 52-week range of 401.45-643.99, average daily share volume of 2.3M, a public-listing history dating back to 1980, approximately 125K full-time employees. These structural characteristics shape how TMO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.87 places TMO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. TMO pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on TMO?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current TMO snapshot

As of June 29, 2026, spot at $503.56, ATM IV 37.40%, IV rank 82.38%, expected move 10.72%. The strangle on TMO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 32-day expiry.

Why this strangle structure on TMO specifically: TMO IV at 37.40% is rich versus its 1-year range, which makes a premium-buying TMO strangle relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 10.72% (roughly $54.00 on the underlying). The 32-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TMO expiries trade a higher absolute premium for lower per-day decay. Position sizing on TMO should anchor to the underlying notional of $503.56 per share and to the trader's directional view on TMO stock.

TMO strangle setup

The TMO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TMO near $503.56, the first option leg uses a $530.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TMO chain at a 32-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TMO shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$530.00	$13.05
Buy 1	Put	$480.00	$11.85

TMO strangle risk and reward

Net Premium / Debit: -$2,490.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$2,490.00
Breakeven(s): $455.10, $554.90
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

TMO strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on TMO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$45,509.00
$111.35	-77.9%	+$34,375.12
$222.69	-55.8%	+$23,241.24
$334.03	-33.7%	+$12,107.36
$445.37	-11.6%	+$973.48
$556.70	+10.6%	+$180.40
$668.04	+32.7%	+$11,314.28
$779.38	+54.8%	+$22,448.16
$890.72	+76.9%	+$33,582.04
$1,002.06	+99.0%	+$44,715.91

When traders use strangle on TMO

Strangles on TMO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TMO chain.

TMO thesis for this strangle

The market-implied 1-standard-deviation range for TMO extends from approximately $449.56 on the downside to $557.56 on the upside. A TMO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TMO IV rank near 82.38% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on TMO at 37.40%. As a Healthcare name, TMO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TMO-specific events.

TMO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TMO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TMO alongside the broader basket even when TMO-specific fundamentals are unchanged. Always rebuild the position from current TMO chain quotes before placing a trade.

Frequently asked questions

What is a strangle on TMO?: A strangle on TMO is the strangle strategy applied to TMO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TMO stock trading near $503.56, the strikes shown on this page are snapped to the nearest listed TMO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TMO strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TMO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,490.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TMO strangle?: The breakeven for the TMO strangle priced on this page is roughly $455.10 and $554.90 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TMO market-implied 1-standard-deviation expected move is approximately 10.72%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on TMO?: Strangles on TMO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TMO chain.
How does current TMO implied volatility affect this strangle?: TMO ATM IV is at 37.40% with IV rank near 82.38%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.